Palexia (Tapentadol)

Palexia is an opioid analgesic that acts on the central nervous system to relieve pain associated with several conditions.

• Acute postoperative pain: Provides effective relief following surgical procedures.
• Chronic musculoskeletal pain: Helps manage persistent pain from conditions such as osteoarthritis.
• Cancer‑related pain: Used as part of a multimodal regimen for severe cancer pain when other opioids are insufficient.

• Tapentadol exerts its analgesic effect through a dual mechanism: it is a µ‑opioid receptor agonist that reduces pain signaling in the central nervous system and it inhibits the reuptake of norepinephrine, enhancing descending inhibitory pain pathways. This combined action results in potent analgesia with a potentially lower incidence of typical opioid side effects.

Tapentadol may cause a range of adverse reactions, most of which are mild to moderate and resolve after continued use or dose adjustment.

Common Side Effects

• Nausea: Feeling of sickness often accompanied by an urge to vomit.
• Constipation: Reduced bowel movements or difficulty passing stool.
• Dizziness: Light‑headed sensation, especially when standing quickly.
• Headache: Mild to moderate pain in the head region.
• Somnolence: Increased sleepiness or fatigue.
• Dry mouth: Reduced salivation leading to a dry oral cavity.

Serious or Rare Side Effects

• Respiratory depression: Slowed or shallow breathing that can be life‑threatening.
• Seizures: Uncontrolled electrical activity in the brain.
• Severe hypotension: Markedly low blood pressure causing faintness.
• Allergic reactions: Rash, itching, swelling, or anaphylaxis.
• Dependence or abuse potential: Risk of developing physical or psychological dependence.
• Adrenal insufficiency: Uncommon hormonal deficiency affecting stress response.

When prescribing Tapentadol, clinicians should consider several safety measures to minimize risk.

• Assess pain severity and prior opioid use: Determine if an opioid is appropriate.
• Review patient medical history: Identify respiratory, hepatic, renal or CNS disorders.
• Monitor for signs of misuse: Watch for craving, dose escalation or doctor shopping.
• Avoid abrupt discontinuation: Taper dose gradually to prevent withdrawal.
• Educate on concomitant CNS depressants: Counsel about increased sedation risk with alcohol or benzodiazepines.
• Store at ambient temperature: Keep tablets in the original container, protect from moisture and heat.

Tapentadol interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, barbiturates): May cause profound sedation or respiratory depression.
• MAO inhibitors: Can precipitate hypertensive crisis or serotonin syndrome.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): Increase tapentadol plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Serotonergic agents (e.g., SSRIs, SNRIs): May increase risk of serotonin syndrome.
• Antihistamines: Can enhance central nervous system depression.
• Diuretics: May exacerbate hypotension when combined with tapentadol.